◼ Archived
Business
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa’s Drug Delivery Technology
Novo Nordisk strikes a $1.3 billion deal with Nanexa to secure long-acting obesity injection technology.
Nanexa
1 trends tracked about this subject — the full history, oldest to newest below.